Comparison

Targaprimir-96 (TFA) European Partner

Item no. HY-135276A-1ea
Manufacturer MedChem Express
Amount 1 ea
Quantity options 100 mg 1 ea
Category
Type Molecules
Specific against other
Citations [1]Velagapudi SP, et al. Design of a small molecule against an oncogenic noncoding RNA. Proc Natl Acad Sci U S A. 2016 May 24;113(21):5898-903.
Smiles OC(C(F)(F)F)=O.O=C(N)CN(C(CN(C(CN(C(CCCOC1=CC=CC(C2=NC3=CC=C(C4=NC5=CC=C(N6CCN(C)CC6)C=C5N4)C=C3N2)=C1)=O)CCC)=O)CCC)=O)CC7=CN(CCCNC(CCCOC8=C(C(C)(C)C)C=C(C9=NC%10=CC=C(N%11CCN(C)CC%11)C=C%10N9)C=C8C(C)(C)C)=O)N=N7
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Shipping Condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
Cancer-programmed cell death
Manufacturer - Targets
Apoptosis; MicroRNA
Shipping Temperature
Room temperature
Molecular Weight
1505.77
Product Description
Targaprimir-96 TFA is a potent inhibitor of microRNA-96 (miR-96) processing. Targaprimir-96 TFA selectively modulates miR-96 production in cancer cells and triggers apoptosis. Targaprimir-96 TFA binds primary miR-96 (pri-miR-96) with low nanomolar affinity. Targaprimir-96 TFA directly engages pri-miR-96 in breast cancer cells and is ineffective on healthy breast cells[1].
Manufacturer - Research Area
Cancer
Solubility
10 mM in DMSO
Manufacturer - Pathway
Apoptosis; Epigenetics
Clinical information
No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 ea
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close